Compare Boston Scientific Corporation (BSX) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Synchrony Financial — how do they compare? Boston Scientific Corporation trades at $43.06 (market cap $66.37B), while Synchrony Financial trades at $74.24 (market cap $24.78B). The key difference: Boston Scientific Corporation is far larger — about 2.7× Synchrony Financial's market cap, and Synchrony Financial pays a 1.63% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | SYF | |
|---|---|---|
Market Cap | $66.37B | $24.78B |
Sector | Health | Financials |
52-Week High | $108.14 | $88.47 |
52-Week Low | $42.63 | $63.78 |
Enterprise Value | $75.94B | — |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
SYF trades at $73.21, up 1.06% today, with a bearish technical signal but strong fundamentals. The stock shows a low P/E of 7.63 and robust profitability with a 24.06% net income margin. Recent earnings beats and a $0.30 dividend highlight operational strength, while analyst consensus is bullish with a $86.38 price target.
Outlook remains positive due to earnings momentum and undervaluation, but risks include economic sensitivity and technical weakness. The stock offers value with upside potential, though investors should monitor loan performance and interest rate impacts on financial results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
